Evolution or revolution in multiple myeloma therapy and the role of the UK.
The knowledge of disease biology as well as the therapeutic landscape in multiple myeloma (MM) has expanded exponentially in recent years. These advances have seen improvements in survivorship, not only in the clinical trial setting but also in the real setting. Importantly there is also every evidence to indicate that such improvements in our understanding and treatments will continue. This article is not intended to be a comprehensive review; rather it aims to give a temporal context to these developments with exemplars, and highlight the central role that UK clinicians, healthcare workers, scientists and most importantly patients and their relatives have played in this revolution.
['Cook|Gordon|G|0000-0001-7196-7364', 'Morris|Curly T C M|CTCM|0000-0003-1717-0412']
D019468:Disease Management D004198:Disease Susceptibility D006801:Humans D009101:Multiple Myeloma D017063:Outcome Assessment, Health Care D006113:United Kingdom
evolution revolution multiple myeloma therapy